Alpine Immune Sciences, Inc.

Welcome to the Alpine Immune Sciences fourth quarter 2022 earnings call. Currently, all participants are in listen-only mode. As a reminder, this event is being recorded. I would now like to introduce Temri Johnson, Senior Director of Investor Relations and Corporate Communications at Alpine. Ms. Johnson, I'll now turn the call over to you.

Thank you, Terri. Good afternoon, and thank you for joining us. With me on the call today are Dr. Mitchell Gold, Executive Chairman and Chief Executive Officer, Dr. Stanford Tang, President and Head of Research and Development, and Paul Rickey, Chief Financial Officer. Before I turn the call over to Mitch, I would like to remind you that we'll be making forward-looking statements during today's call. These forward-looking statements are based on our current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events potential publications of clinical data, and expectations regarding the sufficiency of cash and investments that differ materially from those anticipated in such forward-looking statements as a result of these risk and uncertainty. You may refer to the most recent SEC filings regarding the risk factors associated with these statements. Mitch, please go ahead.

Thank you, Tamrae. Alpine is off to a strong start in 2023, driven by progress in the development of COVID-19 access. a potentially best-in-class dual inhibitor of the BAF inhibitor cytokines with a convenient once every four weeks subcutaneous dosing regimen that we believe has the potential to benefit patients living with multiple types of autoimmune or inflammatory diseases. I'm pleased to announce that we recently achieved a significant milestone with the initiation of the Ruby 3 BASC study, our first patient-based study for the program. which will study poietatic tests in autoimmune glomerulonephritis indications, including IgA nephropathy, lupus nephritis, and primary membranous nephropathy. Although still early in development, investigator enthusiasm for the program and interest in participating in the RUBI3 study is highly encouraged. In addition to RUBI3, we are planning to initiate the RUBI4-BEST study in autoimmune cytopenias in the second quarter of 2023. This includes autoimmune thrombocytopenia, warm autoimmune hemolytic anemia, and cold aglutinous disease. We expect to share initial data from both the RUBI3 and RUBI4 basket studies by the end of this year. We see broad development potential for Povatex except in multiple indications beyond the basket studies, including our RUBI2 study in systemic lupus erythematosus, as well as neurologic, dermatologic, and other rheumatic disease indications. We recently signed a collaboration with Truvada to help accelerate the broad development of COVID tax steps across these multiple indications. With an increasingly competitive and sometimes challenging clinical trial environment, Truvada gives us access to its 28 partner members who provide 16% of patient care in the United States. In addition to our own efforts, we will leverage Truveta's platform and analytics capabilities to more quickly identify and recruit study participants for Ruby 3 and Ruby 4 with the potential to benefit most from Povitaciseps. We believe Povitaciseps has the potential to be a pipeline and a product. With our strong balance sheet and promising preclinical and phase 1 healthy volunteer data, we are rapidly moving forward with a robust development plan for Povitaciseps. And now I'll hand the call over to Stanford to review our progress, provide updates, and a broad general plan for BOVI in more detail. Stanford?